Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24075688 | 0.81 | TSHR (0.41) | TSHRDYRK1AADORA1NPC1RAB9A | |
| SCHEMBL17610074 | 0.81 | TSHR (0.41) | TSHRDYRK1AADORA1NPC1RAB9A | |
| SCHEMBL24075689 | 0.81 | TSHR (0.41) | TSHRDYRK1AADORA1NPC1RAB9A | |
| SCHEMBL24075800 | 0.77 | TSHR (0.39) | TSHRDYRK1AADORA1NPC1RAB9A | |
| SCHEMBL34467553 | 0.73 | DYRK1A (0.46) | DYRK1AADORA1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL13035816 | 0.69 | TSHR (0.67) | TSHRADORA1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL659214 | 0.69 | TSHR (0.71) | TSHRNPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL31569426 | 0.69 | DYRK1A (0.39) | TSHRDYRK1AADORA1NPC1RAB9A | |
| SCHEMBL14903802 | 0.68 | — | — | |
| SCHEMBL1770346 | 0.67 | MAPT (0.42) | TSHRNPC1RAB9ASMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210380591-A1 | ANTHELMINTIC HETEROCYCLIC COMPOUNDS | Boehringer Ingelheim Animal Health USA Inc. (US) | 2021-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210380591-A1 | ANTHELMINTIC HETEROCYCLIC COMPOUNDS | AADAC, HNMT, HRH4 | TSHR 4357/4885DYRK1A 4761/4885ADORA1 2860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.